Literature DB >> 20298969

The worldwide societal costs of dementia: Estimates for 2009.

Anders Wimo1, Bengt Winblad, Linus Jönsson.   

Abstract

BACKGROUND: The purpose of this study was to update the previous estimate of the worldwide cost of dementia in 2005 to 2009.
METHODS: The cost model is based on prevalence estimates, country and region-specific data on Gross Domestic Product per person and average wage, with results from previously published cost-of-illness studies in different countries. Prevalence figures are updated to 2009 and costs were adjusted to 2009 constant US dollars ($).
RESULTS: The total worldwide societal cost of dementia, based on a dementia population of 34.4 million demented persons, was estimated to $422 billion in 2009, including $142 billion for informal care (34%).
CONCLUSIONS: The worldwide cost of dementia has increased by 34% (18% in fixed prices) between 2005 and 2009. 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20298969     DOI: 10.1016/j.jalz.2010.01.010

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  127 in total

1.  Costs of dementia in Hungary.

Authors:  K Érsek; T Kovács; A Wimo; K Kárpati; V Brodszky; M Péntek; L Jönsson; A Gustavsson; D McDaid; P A Kenigsberg; H Valtonen; L Gulácsi
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

2.  Latent classes of course in Alzheimer's disease and predictors: the Cache County Dementia Progression Study.

Authors:  Jeannie-Marie S Leoutsakos; Sarah N Forrester; Christopher D Corcoran; Maria C Norton; Peter V Rabins; Martin I Steinberg; Joann T Tschanz; Constantine G Lyketsos
Journal:  Int J Geriatr Psychiatry       Date:  2014-11-03       Impact factor: 3.485

Review 3.  The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.

Authors:  Jaclyn Cappell; Nathan Herrmann; Stephen Cornish; Krista L Lanctôt
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

4.  Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease.

Authors:  H Fillit; J Cummings; P Neumann; T McLaughlin; P Salavtore; C Leibman
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

5.  Design and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy.

Authors:  Zhihui Qin; Jia Luo; Lawren VandeVrede; Ehsan Tavassoli; Mauro Fa'; Andrew F Teich; Ottavio Arancio; Gregory R J Thatcher
Journal:  J Med Chem       Date:  2012-07-24       Impact factor: 7.446

6.  Substituted dithiazole piperazine benzamides as novel amyloid beta peptide reducing agents.

Authors:  Hongjie Wang; Ruizhi Wang; Madepalli K Lakshmana; Adel Nefzi
Journal:  Bioorg Med Chem Lett       Date:  2014-08-13       Impact factor: 2.823

7.  Trajectories of cognitive decline by driving mobility: evidence from the Health and Retirement Study.

Authors:  Moon Choi; Matthew C Lohman; Briana Mezuk
Journal:  Int J Geriatr Psychiatry       Date:  2013-09-10       Impact factor: 3.485

Review 8.  Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease.

Authors:  Qin Nie; Xiao-guang Du; Mei-yu Geng
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

9.  Four sensitive screening tools to detect cognitive dysfunction in geriatric emergency department patients: brief Alzheimer's Screen, Short Blessed Test, Ottawa 3DY, and the caregiver-completed AD8.

Authors:  Christopher R Carpenter; Elizabeth R Bassett; Grant M Fischer; Jonathan Shirshekan; James E Galvin; John C Morris
Journal:  Acad Emerg Med       Date:  2011-04       Impact factor: 3.451

Review 10.  Regenerative medicine in Alzheimer's disease.

Authors:  Kevin M Felsenstein; Kate M Candelario; Dennis A Steindler; David R Borchelt
Journal:  Transl Res       Date:  2013-11-08       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.